8-KEarnings & ResultsExhibits & Filings

Elevance Health, Inc. 8-K Report, Financial Results (Oct 20, 2021)

Filed October 20, 2021For Securities:ELV

Summary

Elevance Health, Inc. (formerly Anthem, Inc.) filed an 8-K on October 19, 2021, to report its financial results for the quarter ended September 30, 2021. This filing primarily serves to incorporate by reference the press release issued on October 20, 2021, which contains the detailed financial performance for the period. Investors should refer to the press release (Exhibit 99.1) for specific figures related to revenue, earnings, and other operational metrics. While this 8-K itself does not provide granular financial data, it signals the release of these results and directs investors to the accompanying press release. The report also includes standard forward-looking statements, outlining potential risks and uncertainties that could affect the company's future performance. Key areas of risk mentioned include the impact of large-scale medical emergencies like COVID-19, healthcare cost trends, regulatory changes, competitive pressures, and risks associated with its pharmacy benefit management (PBM) business.

Key Highlights

  • 1Elevance Health (Anthem) filed an 8-K to announce its Q3 2021 financial results.
  • 2The report incorporates by reference a press release (Exhibit 99.1) containing the detailed financial results for the quarter ended September 30, 2021.
  • 3Investors should consult the press release for specific financial performance data.
  • 4The filing includes a comprehensive list of forward-looking statements and associated risks.
  • 5Key risk factors discussed include impacts from public health emergencies (e.g., COVID-19), healthcare cost trends, and regulatory environments.
  • 6The company also highlights risks related to its PBM operations and competitive market dynamics.

Frequently Asked Questions

The primary purpose of this 8-K filing is to officially report that Elevance Health, Inc. (then operating as Anthem, Inc.) released its financial results for the quarter ended September 30, 2021. It directs investors to the press release (Exhibit 99.1) which contains the detailed financial information.

The specific financial results for the quarter ended September 30, 2021, are detailed in the press release furnished as Exhibit 99.1 to this 8-K filing. Investors should refer to that document for revenue, earnings per share, and other key financial metrics.

No, this 8-K filing itself does not contain new financial data. It is an announcement that the results have been released and refers investors to the accompanying press release (Exhibit 99.1) for the actual financial details.

The filing outlines numerous risks and uncertainties. Significant risks include the ongoing impact of large-scale medical emergencies like COVID-19, trends in healthcare costs and utilization, regulatory changes (including the Affordable Care Act), competitive pressures within the healthcare industry, and specific risks related to the company's pharmacy benefit management (PBM) business.